SAMPLES PB group 1 AA and RP (n = 11) group 2 Pca in prostate biopsy (n = 11) group 3 BPH in prostate biopsy (n = 20) Frozen tissues Neoplastic and non neoplastic prostate tissues (n = 6) Non prostatic tissues (n = 6) Cell lines (n = 6) prostatic (n = 2) non prostatic (n = 4) PB = peripheral blood RT = radical prostatectomy AA = androgen ablation Group 1 (treated CaP) Total (n = 11) subtype 1 without recurrence (n = 5) subtype 2 with recurrence (n = 6) Gleason score 4–7 (n = 9) 8 (n = 2) TNM Organ-confined disease (n = 7) T2 N0 M0 (n = 7) Extraprostatic disease (n = 4) T3 N0 M0 (n = 2) T3 N1M0 and T3 N2M0 (n = 2) P503S+ No patients (%) 2 (40) 5 (83) 4 (44.44) 2 (100) 4 (57.14) 1 (50) 2 (100) BMC Cancer 2005, 5:111 http://www.biomedcentral.com/1471-2407/5/111 Table 1: RT-PCR assay in peripheral blood, in different tissues and cell lines. Table 2: p503S, p504S and p510S positive cells in peripheral blood of patients with prostate cancer (CaP) in relation to Gleason score and TNM stage. RT-PCR positive negative positive negative positive negative positive negative positive negative positive negative positive negative P503S No (%) 7 (63.63) 4(36.36) 2 (18.18) 9 (81.81) 5 (25) 15 (75) 4 (66.66) 2 (33.33) 6 (100) 0 2 (100) 0 4 (100) 0 P504S+ No patients (%) 2 (40) 5 (83) 6 (66.66) 2 (100) 5 (71.42) 1 (50) 1 (50) P504S No (%) 7 (63.63) 4(36.36) 9 (81.81) 2 (18.18) 11 (55) 9 (45) 4 (66.66) 2 (33.33) 1(16.66) 5 (83.33) 2 (100) 0 2 (50) 2 (50) P510S No (%) 11 (100) 0 11 (100) 0 15 (75) 5 (25) 5 (83.83) 1 (16.16) 2 (33,33) 4 (66.66) 2 (100) 0 2 (50) 2 (50) P510S+ No patients (%) 5 (100) 6 (100) 9 (100) 2 (100) 7 (100) 2 (100) 2 (100) Page 3 of 7 (page number not for citation purposes)